In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. Copyright © 2011 American Society for Reproductive Medicine, Published by Elsevier Inc.
Essah, P. A., Arrowood, J. A., Cheang, K. I., Adawadkar, S. S., Stovall, D. W., & Nestler, J. E. (2011). Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility, 96(2). https://doi.org/10.1016/j.fertnstert.2011.05.091